This prospective, randomized study, comparing sirolimus to cyclosporine in renal transplant
recipients, has two major objectives:
1. -To determine the incidence and the degree of interstitialfibrosis and arteriosclerosis,
as wel as the glomerular volume in protocol biopsies at 6 months in sirolimus-and in
cyclosporine-treated renal allograft recipients, by means of quantitative computerized
image analysis.
- To determine the prognostic implication of these morphologic changes.
2. To study the expression of genes, involved in inflammation and fibrosis, in protocol
biopsies at 6 months in sirolimus-and cyclosporine-treated renal allograft recipients.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Antwerp
Collaborators:
Hoffmann-La Roche Wyeth is now a wholly owned subsidiary of Pfizer